Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Blood (2019) 134 (Supplement_1): 4341.

https://doi.org/10.1182/blood-2019-128854

Published: 2019

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Judith Lind, PhD, Felix Czernilofsky, Sonia Vallet, MD, Fengjuan Fan, PhD, Martin Sattler, PhD, Latifa Bakiri, Erwin F Wagner, PhD, Martin Percherstorfer, MD, Klaus Podar, MD PhD

Blood (2019) 134 (Supplement_1): 4415.

https://doi.org/10.1182/blood-2019-125202

Published: 2019

Journal Articles

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

Stefano Malvestiti, Fengjuan Fan, PhD, Muhammad Hasan Bashari, MD, Eugenio Morelli, MD, Sonia Vallet, MD, Martin Sattler, PhD, Latifa Bakiri, PhD, Anja Seckinger, MD, Dirk Hose, MD, Hartmut Goldschmidt, MD, Inka Zörnig, PhD, Martin Pecherstorfer, MD, Erwin Wagner, PhD, Pierfrancesco Tassone, MD, Dirk Jäger, MD, Klaus Podar, MD MSc PhD

Blood (2016) 128 (22): 2091.

https://doi.org/10.1182/blood.V128.22.2091.2091

Published: 2016

Journal Articles

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Fengjuan Fan, PhD, Sonia Vallet, MD, Martin Sattler, PhD, Giovanni Tonon, MDPhD, Muhammad Hasan Bashari, Latifa Bakiri, PhD, Hartmut Goldschmidt, MD, Erwin F. Wagner, PhD, Dirk Jaeger, MD, Klaus Podar, MD PhD

Blood (2014) 124 (21): 3446.

https://doi.org/10.1182/blood.V124.21.3446.3446

Published: 2014

Journal Articles

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1 128–350 Triggers MM Cell Death V ia c- Jun Upregulation

Fengjuan Fan, PhD, Giovanni Tonon, MD PhD, Martin Sattler, PhD, Alexander Schimming, Hartmut Goldschmidt, MD, PhD, Joseph Opferman, Ph.D, Kenneth C. Anderson, MD, Dirk Jaeger, MD, Klaus Podar, MD, PhD

Blood (2012) 120 (21): 3959.

https://doi.org/10.1182/blood.V120.21.3959.3959

Published: 2012

Journal Articles

Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).

Teru Hideshima, M.D., Ph.D., Constantine S. Mitsiades, MD, PhD, Hiroshi Ikeda, MD, PhD, Dharminder Chauhan, PhD, Noopur Raje, M.D., Gullu Gorgun, PhD, Mariateresa Fulciniti, PhD, Diana Cirstea, MD, Giulia Perron, MD, Loredana Santo, M.D., Ayaka Hideshima, Klaus Podar, MD, MSc, PhD, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Daniel R. Carrasco, MD, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 295.

https://doi.org/10.1182/blood.V114.22.295.295

Published: 2009

Journal Articles

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.

Klaus Podar, MD, PhD, Alexander Zimmerhackl, DI, Ursula Hainz, PhD, Mariateresa Fulciniti, PhD, Sonia Vallet, MD., Dian Olsen, MSc, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, Ph.D, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1850.

https://doi.org/10.1182/blood.V114.22.1850.1850

Published: 2009

Journal Articles

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

Iris Breitkreutz, Marc S Raab, Olaf Christensen, Alexander Zimmerhackl, Jing Zhang, Simona Blotta, Teru Hideshima, Dharminder Chauhan, Scott Wilhelm, Kenneth C Anderson, MD, Klaus Podar, MD, MSc, PhD

Blood (2008) 112 (11): 2766.

https://doi.org/10.1182/blood.V112.11.2766.2766

Published: 2008

Journal Articles

C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications

Klaus Podar, MD, MSc, PhD, Jing Zhang, MS, Giovanni Tonon, MD, PHD, Clemens Grabher, MSc, PHD, Samir Lababidi, PHD, Marc S Raab, MD, Sonia Vallet, MD, Yiming Zhou, PHD, Marie-Astrid Cartron, MS, Martin Sattler, PhD, Dharminder Chauhan, JD, PHD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2750.

https://doi.org/10.1182/blood.V112.11.2750.2750

Published: 2008

Journal Articles

Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity

Klaus Podar, MD, MSc, PhD, Jing Zhang, MS, Alexander Zimmerhackl, DI, Daniela Barila, PHD, Sonia Vallet, MD, Martin Sattler, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PHD, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 2751.

https://doi.org/10.1182/blood.V112.11.2751.2751

Published: 2008

Journal Articles

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Giovanni Tonon, MD, Johannes H. Fruehauf, MD, Iris Breitkreutz, MD, Boris K. Lin, MD, PhD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 258.

https://doi.org/10.1182/blood.V110.11.258.258

Published: 2007

Journal Articles

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Sonia Vallet, MD, Noopur Raje, MD, MariaTeresa Fulciniti, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Samantha Pozzi, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Siddhartha Mukherjee, MD, Nileshwari Vaghela, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2503.

https://doi.org/10.1182/blood.V110.11.2503.2503

Published: 2007

Journal Articles

The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.

Klaus Podar, MD, PhD, Jing Zhang, MSc, Marc S. Raab, MD, Sonia Vallet, MD, Mariateresa Fulciniti, MSc, Martin Sattler, PhD, Yutaka Ikeda, MD, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2507.

https://doi.org/10.1182/blood.V110.11.2507.2507

Published: 2007

Journal Articles

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

Steven Le Gouill, MD, PhD, Klaus Podar, MD PhD, Jing Zhang, Teru Hideshima, MD PhD, Martine Amiot, PhD, Chauhan Dharminder, PhD, Jean-Luc Harousseau, MD, Kenneth Anderson, MD

Blood (2007) 110 (11): 1501.

https://doi.org/10.1182/blood.V110.11.1501.1501

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.

Margret S. Rodrigues, PhD, Jeffrey R. Gonneville, BS, Klaus Podar, MD, PhD, David M. Weinstock, MD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2007) 110 (11): 2937.

https://doi.org/10.1182/blood.V110.11.2937.2937

Published: 2007

Journal Articles

CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.

Sonia Vallet, MD, Noopur Raje, MD, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Tanyel Kizeltepe, PHD, Hiroshi Yasui, MD, Shweta Chhetri, Enrique M. Ocio, MD, Janice Jin, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3494.

https://doi.org/10.1182/blood.V108.11.3494.3494

Published: 2006

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

NARROW

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1 128–350 Triggers MM Cell Death V ia c- Jun Upregulation

Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications

Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells.

CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only